S100B Serum Levels Predict Treatment Response in Patients with Melancholic Depression
| Autor: | Ambree, O, Bergink, Veerle, Grosse, L, Alferink, J, Drexhage, Hemmo, Rothermundt, M, Arolt, V, Birkenhager, T.K. |
|---|---|
| Přispěvatelé: | Psychiatry, Immunology |
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Imipramine Time Factors Venlafaxine Hydrochloride Venlafaxine S100 Calcium Binding Protein beta Subunit Melancholic depression Severity of Illness Index treatment resistance 03 medical and health sciences 0302 clinical medicine Internal medicine Severity of illness medicine Humans Major depression Pharmacology (medical) antidepressant response Psychiatry predictive biomarker neurotrophic factor False Negative Reactions Depression (differential diagnoses) Aged Pharmacology Psychiatric Status Rating Scales Depressive Disorder Middle Aged medicine.disease Prognosis Antidepressive Agents 030227 psychiatry 3. Good health Psychiatry and Mental health Treatment Outcome Linear Models Biomarker (medicine) Antidepressant Female Psychology 030217 neurology & neurosurgery Biomarkers Blood Chemical Analysis medicine.drug Research Article |
| Zdroj: | International Journal of Neuropsychopharmacology International Journal of Neuropsychopharmacology, 19(3). Oxford University Press |
| ISSN: | 1469-5111 1461-1457 |
| Popis: | Background: There is an ongoing search for biomarkers in psychiatry, for example, as diagnostic tools or predictors of treatment response. The neurotrophic factor S100 calcium binding protein B (S100B) has been discussed as a possible predictor of antidepressant response in patients with major depression, but also as a possible biomarker of an acute depressive state. The aim of the present study was to study the association of serum S100B levels with antidepressant treatment response and depression severity in melancholically depressed inpatients. Methods: After a wash-out period of 1 week, 40 inpatients with melancholic depression were treated with either venlafaxine or imipramine. S100B levels and Hamilton Depression Rating Scale (HAM-D) scores were assessed at baseline, after 7 weeks of treatment, and after 6 months. Results: Patients with high S100B levels at baseline showed a markedly better treatment response defined as relative reduction in HAM-D scores than those with low baseline S100B levels after 7 weeks (P=.002) and 6 months (P=.003). In linear regression models, S100B was a significant predictor for treatment response at both time points. It is of interest to note that nonresponders were detected with a predictive value of 85% and a false negative rate of 7.5%. S100B levels were not associated with depression severity and did not change with clinical improvement. Conclusions: Low S100B levels predict nonresponse to venlafaxine and imipramine with high precision. Future studies have to show which treatments are effective in patients with low levels of S100B so that this biomarker will help to reduce patients' burden of nonresponding to frequently used antidepressants. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|